CLEXANE 100 Mg/Ml Solution for Injection Ireland - Inggeris - HPRA (Health Products Regulatory Authority)

clexane 100 mg/ml solution for injection

pco manufacturing - enoxaparin sodium - solution for injection - 100 mg/ml - heparin group

Clexane 300mg/3ml solution for injection multidose vials United Kingdom - Inggeris - MHRA (Medicines & Healthcare Products Regulatory Agency)

clexane 300mg/3ml solution for injection multidose vials

sanofi - enoxaparin sodium - solution for injection - 100mg/1ml

Clexane 4 000 IU (40 mg)/0,4 ml inj. sol. s.c./i.v. pre-filled syr. Belgium - Inggeris - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

clexane 4 000 iu (40 mg)/0,4 ml inj. sol. s.c./i.v. pre-filled syr.

sanofi belgium sa-nv - enoxaparin sodium 20 mg/0,2 ml - solution for injection in pre-filled syringe - 4000 iu (40 mg)/0,4 ml - enoxaparin sodium 100 mg/ml - enoxaparin

Clexane 2 000 IU (20 mg)/0,2 ml inj. sol. s.c./i.v. pre-filled syr. Belgium - Inggeris - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

clexane 2 000 iu (20 mg)/0,2 ml inj. sol. s.c./i.v. pre-filled syr.

sanofi belgium sa-nv - enoxaparin sodium 20 mg/0,2 ml - solution for injection in pre-filled syringe - 2000 iu (20 mg)/0,2 ml - enoxaparin sodium 100 mg/ml - enoxaparin

Clexane 8 000 IU (80 mg)/0,8 ml inj. sol. s.c./i.v. pre-filled syr. Belgium - Inggeris - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

clexane 8 000 iu (80 mg)/0,8 ml inj. sol. s.c./i.v. pre-filled syr.

sanofi belgium sa-nv - enoxaparin sodium 20 mg/0,2 ml - solution for injection in pre-filled syringe - 8000 iu (80 mg)/0,8 ml - enoxaparin sodium 100 mg/ml - enoxaparin

Clexane 10 000 IU (100 mg)/1 ml inj. sol. s.c./i.v. pre-filled syr. Belgium - Inggeris - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

clexane 10 000 iu (100 mg)/1 ml inj. sol. s.c./i.v. pre-filled syr.

sanofi belgium sa-nv - enoxaparin sodium 20 mg/0,2 ml - solution for injection in pre-filled syringe - 10000 iu (100 mg)/1 ml - enoxaparin sodium 100 mg/ml - enoxaparin

Clexane 6 000 IU (60 mg)/0,6 ml inj. sol. s.c./i.v. pre-filled syr. Belgium - Inggeris - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

clexane 6 000 iu (60 mg)/0,6 ml inj. sol. s.c./i.v. pre-filled syr.

sanofi belgium sa-nv - enoxaparin sodium 20 mg/0,2 ml - solution for injection in pre-filled syringe - 6000 iu (60 mg)/0,6 ml - enoxaparin sodium 100 mg/ml - enoxaparin

Clexane 15 000 IU (150 mg)/1 ml inj. sol. s.c./i.v. pre-filled syr. Belgium - Inggeris - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

clexane 15 000 iu (150 mg)/1 ml inj. sol. s.c./i.v. pre-filled syr.

sanofi belgium sa-nv - enoxaparin sodium 90 mg/0,6 ml - solution for injection in pre-filled syringe - 15000 iu (150 mg)/1 ml - enoxaparin sodium 150 mg/ml - enoxaparin

Clexane 12 000 IU (120 mg)/0,8 ml inj. sol. s.c./i.v. pre-filled syr. Belgium - Inggeris - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

clexane 12 000 iu (120 mg)/0,8 ml inj. sol. s.c./i.v. pre-filled syr.

sanofi belgium sa-nv - enoxaparin sodium 90 mg/0,6 ml - solution for injection in pre-filled syringe - 12000 iu (120 mg)/0,8 ml - enoxaparin sodium 150 mg/ml - enoxaparin

CRUSIA Israel - Inggeris - Ministry of Health

crusia

tzamal bio-pharma ltd - enoxaparin sodium - solution for injection - enoxaparin sodium 100 mg / 1 ml - enoxaparin - crusia is indicated in adults for:•prophylaxis of venous thromboembolic disease in moderate and high risk surgical patients, in particular those undergoing orthopaedic or general surgery including cancer surgery.•prophylaxis of venous thromboembolic disease in medical patients with an acute illness (such as acute heart failure, respiratory insufficiency, severe infections or rheumatic diseases) and reduced mobility at increased risk of venous thromboembolism.•treatment of deep vein thrombosis (dvt) and pulmonary embolism (pe), excluding pe ikely to require thrombolytic therapy or surgery. prevention of thrombus formation in extra corporeal circulation during haemodialysis.•acute coronary syndrome:-treatment of unstable angina and non st-segment elevation myocardial infarction (nstemi), in combination with oral acetylsalicylic acid.-treatment of acute st-segment elevation myocardial infarction (stemi) including patients to be managed medically or with subsequent percutaneous coronary intervention (pci).